Ipivivint

Research use only, not for human use.

Ipivivint (Compound 38) is an orally active and potent CDC-like kinase (CLK) inhibitor with EC50s of 1 nM, 7 nM for CLK2 and CLK3, respectively. Ipivivint inhibits Wnt pathway (EC50=13 nM).

Ipivivint (compound 38) is a potent CDC-like kinase (CLK) inhibitor with EC50s of 1 nM, 7 nM for CLK2 and CLK3, respectively. Ipivivint inhibits Wnt pathway (EC50=13 nM).

Western Blot Analysis Cell Line:SW480 cells Concentration:0.01~10 μM Incubation Time:1 hourResult:Potently inhibited SRSF5/6 phosphorylation.Apoptosis Analysis Cell Line:SW480 cells Concentration:0.01~10 μM Incubation Time:0.03 μM~3 μM Result:Induced apoptosis.RT-PCR Cell Line:HEK-293T cells Concentration:0.3~3 μM Incubation Time:1 hour Result:Inhibited Wnt/β-catenin signaling induced by Wnt3a.Immunofluorescence Cell Line:SW480 cells Concentration:0.3~10 μM Incubation Time:6 hours Result:Increased nuclear speckle enlargement.

Animal Model:Foxn1 mice Dosage:25 mg/kg Administration:P.o.Result:Potently inhibited tumor SRSF6 phosphorylation.

———

Others

Other Targets

CDK2: 1 nM (EC50, CDK3: 7 nM (EC50)

———

———

1481617-15-5

464.5

C26H21FN8

>98% (HPLC)

DMSO : 3.33 mg/mL (7.17 mM; ultraphonic (<80°C); )

———

——

(-20℃)

With Ice Pack

≥ 2 years